Opendata, web and dolomites

NovAnI SIGNED

Indentification and optimisation of novel anti-infective agents using multiple hit-identification strategies

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NovAnI project word cloud

Explore the words cloud of the NovAnI project. It provides you a very rough idea of what is the project "NovAnI" about.

absent    agent    methicillin    transporters    der    difficult    humans    dxs    importers    biosynthetic    thereby    antituberculotic    provides    biochemical    give    combination    dna    gram    antimalarial    strategies    cutting    scaffolds    circumventing    serious    pharmacologists    explored    staphylococcus    coupling    peculiar    threat    synthetic    drugs    crystallographers    vitamin    first    anti    given    wall    negative    infectives    employing    million    causative    few    deaths    platform    pathogens    identification    drug    erc    protein    repair    exhaustion    position    synergistic    cell    hit    infections    infective    builds    incidence    me    agents    diseases    chemistry    small    emergence    potentially    place    unconventional    action    resistant    un    rapid    biochemists    mrsa    collaborations    sliding    dnan    tuberculosis    edge    resistance    energy    fact    investment    return    flexibility    bacteria    positive    clamp    mode    urgently    health    crossing    interdisciplinary    mycobacterium    expertise    medicinal    antibacterial    aureus    goals    context    organic    inhibitors    molecule    polymerase    selectivity    excellent   

Project "NovAnI" data sheet

The following table provides information about the project.

Coordinator
HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH 

Organization address
address: INHOFFENSTRASSE 7
city: BRAUNSCHWEIG
postcode: 38124
website: www.helmholtz-hzi.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 1˙499˙367 €
 EC max contribution 1˙499˙367 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2017-STG
 Funding Scheme ERC-STG
 Starting year 2018
 Duration (year-month-day) from 2018-02-01   to  2023-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH DE (BRAUNSCHWEIG) coordinator 1˙499˙367.00

Map

 Project objective

Given the rapid emergence of anti-infective resistance, drugs with a novel mode of action are urgently needed. Because of an exhaustion of existing strategies, a low return on investment and the fact that anti-infectives are difficult to develop (e.g., crossing the peculiar cell wall of Mycobacterium tuberculosis), promising un(der)explored targets and unconventional hit-identification strategies are needed.

I have selected three anti-infective targets based on their biochemical context for which few or no small-molecule inhibitors are known:

1) The antimalarial and antituberculotic drug target DXS is part of a unique biosynthetic pathway for pathogens that is absent in humans, thereby circumventing selectivity issues. Both diseases are a serious health threat with around 1.9 million deaths per year. 2) Energy-coupling factor transporters are essential vitamin importers for pathogens such as Staphylococcus aureus, the causative agent of methicillin-resistant Staphylococcus aureus (MRSA) infections. 3) The DNA polymerase sliding clamp DnaN has polymerase and DNA repair activities and is an excellent drug target for the development of antibacterial agents against Gram-negative and –positive bacteria given the low incidence of resistance development.

I will address these targets, employing a unique combination of potentially synergistic hit-identification strategies that take into account protein flexibility, provide access to novel scaffolds and give me a cutting edge for the development of novel anti-infectives.

This ERC proposal builds on my experience with the first two targets and provides an excellent platform for the new target DnaN. My expertise in synthetic organic and medicinal chemistry and established hit-identification strategies together with my collaborations with protein crystallographers, biochemists and pharmacologists place me in an excellent position for not only achieving the goals of this interdisciplinary proposal but also going beyond it.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NOVANI" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NOVANI" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

CoolNanoDrop (2019)

Self-Emulsification Route to NanoEmulsions by Cooling of Industrially Relevant Compounds

Read More  

OAlipotherapy (2018)

Long-retention liposomic drug-delivery for intra-articular osteoarthritis therapy

Read More  

AST (2019)

Automatic System Testing

Read More